Sobi Maintains Grip On RSV Market – For Now
Though Competition Is Coming
Executive Summary
Vaccines and new antibody drugs are set to transform the respiratory syncytial virus space but for now, the Swedish rare disease specialist’s 25-year old offering Synagis is enjoying increased demand.